Showing results (71-80 of 721) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|May 21, 2022
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b studyFrancesco Passamonti, Francesca Palandri, Guray Saydam, et al.
The Lancet. Haematology|June 30, 2022
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?Michael J Hochman, Amy E DeZern
The Lancet. Haematology|July 2, 2022
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trialFrank Cools, Saverio Virdone, Jitendra Sawhney, et al.
The Lancet. Haematology|February 29, 2020
Imaging haemopoietic stem cells and microenvironment dynamics through transplantationKirsten M Williams, Jennifer Holter Chakrabarty
The Lancet. Haematology|March 6, 2020
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysisMarijke Linschoten, Janine A M Kamphuis, Anna van Rhenen, et al.
The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.
The Lancet. Haematology|August 1, 2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trialJustin Taylor, Xiaoli Mi, Alexander V Penson, et al.
The Lancet. Haematology|July 7, 2020
Effects of the COVID-19 pandemic on supply and use of blood for transfusionSimon J Stanworth, Helen V New, Torunn O Apelseth, et al.
The Lancet. Haematology|April 24, 2021
The power of specialty palliative care: moving towards a systems perspectiveAmber E Barnato, Inas S Khayal
The Lancet. Haematology|April 7, 2023
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 studyXiaofan Liu, Hu Zhou, Yu Hu, et al.
Pageof 73